Brookline Capital Markets Comments on CRDL Q3 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Analysts at Brookline Capital Markets decreased their Q3 2026 earnings per share estimates for Cardiol Therapeutics in a report issued on Wednesday, April 1st. Brookline Capital Markets analyst F. Ahmed now forecasts that the company will earn ($0.08) per share for the quarter, down from their previous forecast of ($0.07). The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. Brookline Capital Markets also issued estimates for Cardiol Therapeutics’ Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.31) EPS.

Cardiol Therapeutics (NASDAQ:CRDL) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.04.

Several other equities analysts have also issued reports on the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 price target on shares of Cardiol Therapeutics in a research note on Monday. raised Cardiol Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 3rd. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Cardiol Therapeutics in a research note on Tuesday, February 10th. Finally, Wall Street Zen raised Cardiol Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $8.50.

Cardiol Therapeutics Trading Up 0.7%

Shares of CRDL opened at $1.40 on Tuesday. The company has a quick ratio of 3.89, a current ratio of 3.89 and a debt-to-equity ratio of 0.01. Cardiol Therapeutics has a 12-month low of $0.80 and a 12-month high of $1.59. The firm has a market capitalization of $156.55 million, a PE ratio of -5.00 and a beta of 0.82. The stock’s fifty day simple moving average is $1.07 and its 200-day simple moving average is $1.05.

Institutional Investors Weigh In On Cardiol Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tejara Capital Ltd increased its holdings in Cardiol Therapeutics by 95.1% in the fourth quarter. Tejara Capital Ltd now owns 5,130,122 shares of the company’s stock valued at $4,893,000 after purchasing an additional 2,500,000 shares during the last quarter. AdvisorShares Investments LLC increased its holdings in Cardiol Therapeutics by 7.3% in the fourth quarter. AdvisorShares Investments LLC now owns 597,977 shares of the company’s stock valued at $570,000 after purchasing an additional 40,589 shares during the last quarter. Bank of America Corp DE increased its holdings in Cardiol Therapeutics by 1,983.0% in the third quarter. Bank of America Corp DE now owns 551,053 shares of the company’s stock valued at $590,000 after purchasing an additional 524,598 shares during the last quarter. Citadel Advisors LLC increased its holdings in Cardiol Therapeutics by 1,132.6% in the third quarter. Citadel Advisors LLC now owns 463,462 shares of the company’s stock valued at $496,000 after purchasing an additional 425,862 shares during the last quarter. Finally, Integrity Alliance LLC. bought a new stake in Cardiol Therapeutics in the fourth quarter valued at about $416,000. Institutional investors own 12.49% of the company’s stock.

Cardiol Therapeutics News Summary

Here are the key news stories impacting Cardiol Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” and a $9.00 target, and materially tightened/raised its model — boosting FY2026 EPS from ($0.41) to ($0.27) and improving FY2027 to ($0.34) (from ($0.51)). The firm also laid out -$0.06 quarterly EPS assumptions across 2026, signaling a more constructive outlook. HC Wainwright estimates
• Positive Sentiment: Canaccord Genuity reaffirmed its “Buy” rating with an $8.00 price target, a substantially higher objective than current levels — reinforcing bullish sentiment among institutional brokers. Benzinga article
• Neutral Sentiment: HC Wainwright’s published quarter-by-quarter EPS assumptions (Q1–Q4 2026 at ~$0.06 loss per share) provide a consistent near-term earnings path but do not introduce new catalysts beyond the improved FY guidance. HC Wainwright quarterly estimates
• Negative Sentiment: Brookline Capital trimmed several near-term estimates: Q3 2026 EPS lowered to ($0.08) from ($0.07), Q4 to ($0.09) and FY2026 to ($0.31) (from $0.29 prior). These downgrades introduce some caution about near-term results and pressure investor expectations. Brookline estimate changes

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.